Evogene

Evogene (NASDAQ: EVGN, TASE: EVGN) is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters.

Nº Q6981538 ★★★

Rare · Organisations

Evogene

Texte en anglais

Evogene (NASDAQ: EVGN, TASE: EVGN) is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters.

Dernier prix

—

Prix plancher

—

Médiane 7 j

—

Ventes 30 j

0

Fourchette 30 j

—

En circulation

0

Cours

Voir le tableau
Datemédiane MinMaxventes

Historique des ventes

Dernière vente
—
Moyenne 30 j
—
Plus bas 30 j
—
Plus haut 30 j
—
Ventes 7 j
0
Ventes 30 j
0

Aucune vente pour l'instant.

Ventes anonymes : ni acheteur ni vendeur. Les chiffres ne comptent que les ventes entre joueurs.

№ Éditions numérotées · 0 frappées Prochain n° 1 · Score ×3
Sur Wikipédia

Texte en anglais Pas encore d'article dans ta langue : extrait en anglais.

Evogene (NASDAQ: EVGN, TASE: EVGN) is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture.

Texte : Wikipédia en anglais, CC BY-SA 4.0. · Image : Litalmam (CC BY-SA 4.0) ·

Cartes voisines

Voir la fiche

Confirmation